261 related articles for article (PubMed ID: 32402357)
1. Advances in the Treatment of Stage III Non-Small Cell Lung Cancer.
Myall NJ; Das M
Clin Chest Med; 2020 Jun; 41(2):211-222. PubMed ID: 32402357
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer.
Melosky B; Juergens R; McLeod D; Leighl N; Brade A; Card PB; Chu Q
Lung Cancer; 2019 Aug; 134():259-267. PubMed ID: 31319991
[TBL] [Abstract][Full Text] [Related]
3. Unmet Clinical Need in the Management of Locally Advanced Unresectable Lung Cancer: Treatment Strategies to Improve Patient Outcomes.
Rajappa S; Sharma S; Prasad K
Adv Ther; 2019 Mar; 36(3):563-578. PubMed ID: 30693419
[TBL] [Abstract][Full Text] [Related]
4. Perspectives on treatment advances for stage III locally advanced unresectable non-small-cell lung cancer.
Cheema PK; Rothenstein J; Melosky B; Brade A; Hirsh V
Curr Oncol; 2019 Feb; 26(1):37-42. PubMed ID: 30853796
[TBL] [Abstract][Full Text] [Related]
5. Patients with unresectable stage III non-small cell lung cancer eligible to receive consolidation therapy with durvalumab in clinical practice based on PACIFIC study criteria.
Sakaguchi T; Ito K; Furuhashi K; Nakamura Y; Suzuki Y; Nishii Y; Taguchi O; Hataji O
Respir Investig; 2019 Sep; 57(5):466-471. PubMed ID: 31104989
[TBL] [Abstract][Full Text] [Related]
6. Induction Immunotherapy Followed by Thoracic Radiation without Chemotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: A Case Series.
Dasari S; Komiya T
Asian Pac J Cancer Prev; 2022 Jan; 23(1):217-220. PubMed ID: 35092391
[TBL] [Abstract][Full Text] [Related]
7. The changing landscape of stage III lung cancer: a literature review.
Patel M; Bruno D; Grubb W; Biswas T
Expert Rev Anticancer Ther; 2020 Aug; 20(8):675-686. PubMed ID: 32667262
[TBL] [Abstract][Full Text] [Related]
8. Feasibility and efficacy of salvage lung resection after definitive chemoradiation therapy for Stage III non-small-cell lung cancer.
Shimada Y; Suzuki K; Okada M; Nakayama H; Ito H; Mitsudomi T; Saji H; Takamochi K; Kudo Y; Hattori A; Mimae T; Aokage K; Nishii T; Tsuboi M; Ikeda N
Interact Cardiovasc Thorac Surg; 2016 Dec; 23(6):895-901. PubMed ID: 27543652
[TBL] [Abstract][Full Text] [Related]
9. Favorable response to pembrolizumab after durvalumab failure in a stage III sarcomatoid carcinoma of the lung: a case report.
Nishino K; Kunimasa K; Kimura M; Inoue T; Tamiya M; Kuhara H; Kumagai T
BMC Pharmacol Toxicol; 2020 Apr; 21(1):26. PubMed ID: 32245391
[TBL] [Abstract][Full Text] [Related]
10. Durvalumab for stage III non-small-cell lung cancer patients: clinical evidence and real-world experience.
Botticella A; Mezquita L; Le Pechoux C; Planchard D
Ther Adv Respir Dis; 2019; 13():1753466619885530. PubMed ID: 31686616
[TBL] [Abstract][Full Text] [Related]
11. Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study.
Hui R; Özgüroğlu M; Villegas A; Daniel D; Vicente D; Murakami S; Yokoi T; Chiappori A; Lee KH; de Wit M; Cho BC; Gray JE; Rydén A; Viviers L; Poole L; Zhang Y; Dennis PA; Antonia SJ
Lancet Oncol; 2019 Dec; 20(12):1670-1680. PubMed ID: 31601496
[TBL] [Abstract][Full Text] [Related]
12. Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
Howington JA; Blum MG; Chang AC; Balekian AA; Murthy SC
Chest; 2013 May; 143(5 Suppl):e278S-e313S. PubMed ID: 23649443
[TBL] [Abstract][Full Text] [Related]
13. Treatment of stage III non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
Ramnath N; Dilling TJ; Harris LJ; Kim AW; Michaud GC; Balekian AA; Diekemper R; Detterbeck FC; Arenberg DA
Chest; 2013 May; 143(5 Suppl):e314S-e340S. PubMed ID: 23649445
[TBL] [Abstract][Full Text] [Related]
14. Role of immunotherapy in stage III nonsmall cell lung cancer.
Wrona A
Curr Opin Oncol; 2019 Jan; 31(1):18-23. PubMed ID: 30489337
[TBL] [Abstract][Full Text] [Related]
15. Utilization and factors precluding the initiation of consolidative durvalumab in unresectable stage III non-small cell lung cancer.
Shaverdian N; Offin MD; Rimner A; Shepherd AF; Wu AJ; Rudin CM; Hellmann MD; Chaft JE; Gomez DR
Radiother Oncol; 2020 Mar; 144():101-104. PubMed ID: 31786421
[TBL] [Abstract][Full Text] [Related]
16. Combined modality therapy for non-small cell lung carcinoma.
Machtay M; Glatstein E
Cancer J; 2002; 8 Suppl 1():S55-67. PubMed ID: 12075703
[TBL] [Abstract][Full Text] [Related]
17. Durvalumab for the treatment of non-small cell lung cancer.
Murakami S
Expert Rev Anticancer Ther; 2019 Dec; 19(12):1009-1016. PubMed ID: 31782989
[No Abstract] [Full Text] [Related]
18. Updates in Local-Regionally Advanced Non-Small Cell Lung Cancer.
Tsao AS; Jolly S; Lee JM
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():553-562. PubMed ID: 31099691
[TBL] [Abstract][Full Text] [Related]
19. Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response.
Machtay M; Lee JH; Stevenson JP; Shrager JB; Algazy KM; Treat J; Kaiser LR
J Thorac Cardiovasc Surg; 2004 Jan; 127(1):108-13. PubMed ID: 14752420
[TBL] [Abstract][Full Text] [Related]
20. Combined modality treatment of non-small-cell lung cancer.
Westeel V; Depierre A
Am J Respir Med; 2003; 2(6):477-90. PubMed ID: 14719987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
